ADRB1 and cardiomyopathy: Given that 29% of asymptomatic individuals and 98% of individuals with cardiomyopathy have been found to be seropositive for anti-β1AR Ab combined with anti-M2R Ab, seropositive individuals without symptoms are likely at risk of developing cardiomyopathy in the future (44).